October 14 – 15, 2025

Troutman Pepper Locke is a proud sponsor of the American Conference Insititute’s (ACI) Forum on Pharma & Biotech Patent Litigation, taking place on October 14-15, 2025, in New York City, NY.

Partner Andrew Zappia will be a panelist on “Forecasting the Future of the PTAB in Bio-Pharma Patent Reviews: When is the PTAB Still a Good Choice?,” on October 14, at 3:15 pm.

The panel will discuss the decline in life sciences patent review cases before the Patent Trial and Appeal Board (PTAB) over the last few years, with many wondering what benefits there are to gain from filing at the PTAB rather than going directly to the district court. Recently, the PTAB announced new procedural processes, including a bifurcated process for consideration of IPR and PGR petitions which is making filings for life sciences patents even less attractive in this forum.

This change, aimed at improving PTAB efficiency, endows the director of the PTAB with more control in granting discretionary denials of IPRs and PGR petitions.

This session will analyze this new process, and other changes at PTAB, as well as when the PTAB is a valid forum for patent redress in the life sciences.